CagriSema Cuts Weight 23–27% Across Menopause Stages, Trial Analysis Shows
A REDEFINE 1 post-hoc analysis reports CagriSema produced 23.1%–26.7% mean weight loss in women across menopause stages, with an FDA decision anticipated in late 2026.
CagriSema Post Hoc Data: 25% Weight Loss in Women as FDA Decision Looms
Two post hoc REDEFINE 1 analyses report 25.0% mean weight loss with investigational CagriSema in women at 68 weeks, with 23.1% to 26.7% across menopause subgroups, as an FDA decision looms.